Clinical Trials
50
Active:12
Completed:33
Trial Phases
3 Phases
Phase 1:24
Phase 2:9
Phase 3:13
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
Phase 1
24 (52.2%)Phase 3
13 (28.3%)Phase 2
9 (19.6%)Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT03887884
- Locations
- 🇺🇸
Acorda Site #1003, Long Beach, California, United States
🇺🇸Acorda Site #1005, Hallandale Beach, Florida, United States
🇺🇸Acorda Site #1002, Orlando, Florida, United States
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: CVT-427 (zolmitriptan inhalation powder)
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT02905227
- Locations
- 🇺🇸
Site #103, North Dartmouth, Massachusetts, United States
🇺🇸Site #102, Lincoln, Nebraska, United States
🇺🇸Site #101, Dallas, Texas, United States
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT02812394
- Locations
- 🇺🇸
Site #001, Dallas, Texas, United States
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: CVT-301, LIPOther: Placebo
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT02807675
- Locations
- 🇺🇸
Site #9015, Fountain Valley, California, United States
🇺🇸Site #9002, Boca Raton, Florida, United States
🇺🇸Site #9017, Hallandale, Florida, United States
A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT02663999
- Locations
- 🇺🇸
Site #001, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found